With the rapid increase in the number of potential psychopharmaceuticals, the need for screening technics has become more acute. In studies of the electrographic patterns of convulsive therapy, the hypothesis evolved that behavioral changes induced by new compounds could be related to their neurophysiologic effects as reflected by the type and degree of electrographic change (1, 2). This suggestion followed a similar one by Wikler (3) who stated that "regardless of the nature of the drug administered, shifts in the pattern of the electroencephalogram in the direction of desynchronization occurred in association with anxiety, hallucinations, fantasies, illusions or tremors, and in the direction of synchronization with euphoria, relaxation or drowsiness." Studies with various psychotropics (4) and anticholinergic hallucinogens (5,6) supported such a relationship. It is the purpose of this preliminary report to describe initial behavioral and electrographic observations with Tofranil t, a new psychopharmaceutical, and to relate these observations to the neurophysiologic-adaptive hypothesis of the mode of action of physiodynamic therapies (1).
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Methods
Two types of studies were undertaken in an open-ward, voluntary hospitalized population. In 28 acute experiments, consecutive patients referred for physiodynamic therapies were tested in the EEG laboratory at various stages of treatment. Tofranil solution (10 mg/ml) was administered intravenously at a set rate (1 ml/40 sec.) until electrographic or behavioral changes became prominent, for a total of 40-125 mg (0.5-mg/kg). Behavioral observation and electrographic recording continued for one to three hours.
A second group of 16 patients manifesting depressive, withdrawn or retarded behavior were referred by their therapists for pharmacotherapy. The patients received daily oral Tofranil, 75-250 mg. Behavioral observations and ERG recordings were made prior to and during treatment. Patients ranged in age from 17 to 58, and were diagnosed as suffering from schizophrenia, manic-depressive and involutional depressive psychoses, and psychoneuroses. Observations I. Acute Studies: On acute administration, there was an initial restlessness, associated with dizziness, dry mouth, "faintness," nausea, and on four occasions, vomiting. These symptoms persisted for 10-20 minutes, and were accompanied by lassitude, heaviness of the extremities and eventual drowsiness. Heart rate was unchanged or slowed. Subsequently, subjects were relaxed, quiet and disinclined to activity, even when returned to their ward.
The electrographic patterns accompanying these behavioral changes were initiated by a gradual decrease in voltages during the injection. By ten minutes, the per cent time alpha and mean alpha voltage had been halved. In four patients with moderate amounts of beta activity, such activity increased in voltage and per cent time. By twenty minutes, in association with behavioral lassitude, low voltage (to 50 microvolts) random theta frequencies (5- In six records with post-convulsive delta activity, there was a marked decrease in voltages and per cent time of slow wave activity. These electrographic patterns persisted for half-an-hour to two hours ( Figure 3 ). There was considerable individual variability in the EEG response. In patients who received 100 mg or more of Tofranil, EEG and behavioral changes were observed in all but three. In six patients, dosage of Tofranil less than 50 mg were not associated with either EEG or behavioral changes.
2. Chronic Administration Studies: Sixteen patients, manifesting depressive symptoms with varying degrees of insomnia, anorexia, withdrawal, and agitation, have received Tofranil medication for four weeks or longer. Medication was given in oral divided doses of 100-250 mg per day. Behavioral changes generally appeared during the second and were maximal during the third week of treatment. The most prominent behavioral adaptation was euphoric denial, which was noted in eight patients. The depressive attitude was no longer apparent. They participated more fully in ward activities, complained less of somatic symptoms, and denied, minimized or displaced their illness on inquiry. Agitation decreased, and complaints of insomnia became less. It became increasingly difficult to discuss significant life relationships as the patients pressed for an early discharge from the hospital.
In three patients somatization and restlessness increased and depressive affect persisted. In two of these, restlessness, insomnia and vomiting led to cessation of therapy. Sweating increased in most patients, but became a focus of attention in these subjects.
No change in symptoms were noted in five patients after four weeks of therapy. While no serious complications of therapy were noted, nausea, increased sweating, vomiting, dryness of the mouth, restlessness and excitement, and increasing insomnia were reported. These were prominent early in therapy, and except for the vomiting and restlessness, did not limit the treatment. In three subjects medication was initially administered parenterally without untoward effects. Abnormal motor patterns and seizures were not noted in these patients at these dosages.
Electrographic studies on chronic administration showed minimal changes. Voltages became lower and record modulation became poorer. Well-defined fast activity became more prominent, and in four subjects low-voltage theta (5-7 cps) activity was noted.
Discussion
These observations indicate that Tofranil is an active central nervous system agent in man, both on oral and intravenous administration. The neurophysiologic effects are rnanifest zelectrographically as desynchronization of rhythms and a shift in frequency spectrum to the slower range. In depressed retarded subjects, Tofranil administration is associated with such behavioral changes as decreased depressive affect with increased participation in ward activities, increased use of denial patterns (7) and occasional excitement.
In comparison to our previous experience with other physiodynamic therapies, the behavioral and electrographic patterns of Tofranil are most like those seen with central anticholinergic agents. We observed desynchronization of frequencies, with an increase in theta activity, to be prominent with experimental anticholinergic compounds such as diethazine and benactyzine* (5, 6) . In those studies, electrographic desynchronization was associated with behavioral alerting, excitement and illusory and hallucinatory activity. On Tofranil administration, similar electrographic patterns of desynchronization were observed, accompanied by euphoria and increased ward participation. While we have not observed hallucinatory activity at our dosage ranges, Lehmann et al. (9) have reported hallucinations and hypomanic excitement in 7 of 84 patients receiving Tofranil.
In earlier reports, Wikler (3, 10) suggested that the electrographic patterns of synchronization and desynchronization reflected neuron systems distinct from those neuron systems subserving such functions as 'sensation,' 'ideation' and 'level of awareness.' While these systems were frequently interlocked, dissociation between EEG pattern and behavior was observable under a variety of drug-induced states. In our earlier studies we were impressed that the electrographic and behavioral patterns seen after induced convulsions, anticholinergic compounds and phrenotropic agents were directly related. On acute administration of Tofranil, however, electrographic desynchronization was associated with clinical sedation. These studies are consistent with Wikler's suggestion.
These observations permit the classification of the neuropharmacologic activity of Tofranil in the central nervous 'system as predominantly anticholinergic. However, we have noted aspects of the electrographic and behavioral patterns reminiscent of increased cholinergic activity. These include the electrographic shift to slower frequencies and sedative, euphoriant behavioral effects. Such observations suggest that there may also be an effective degree of central cholinergic activity.
Su:m:mary
Intravenous administration of Tofranil in 28 voluntary, open-ward psychiatric patients elicited electrographic patterns of desynchronization and an increase of theta rhythms, associated with behavioral alerting, relaxation and lassitude.
Chronic administration of oral Tofranil in 16 depressed and retarded psychiatric subjects elicited behavioral adaptations of euphoric denial in eight, restlessness°A recent report by Abood and Meduna (8) relates the behavioral improvement in depressed patients with JB-329, a new central anticholinergic agent which has similar electrographic patterns. S170 CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL Vol. 4, 1959 and somatization in three and no change in five. During the fifth week of administration, electrographic desynchronization was manifest.
It is concluded that Tofranil is an active central nervous system agent, with a spectrum of activity most like experimental anticholinergic hallucinogens. The theoretic significance for neurophysiologic-behavioral constructs is briefly discussed. The question was asked whether administration of a large dose of Tofranil once a day would not be as effective as multiple dosage. This would of course be a tremendous saving in the time of the nurses involved. In answer it was stated that Tofranil is best given not in one large daily dose but in a series of small doses such as 2 tablets t.i.d. It was also brought out that Tofranil has a tremendous influence on transference phenomena and that these can be analyzed in dreams and symbolisms. While such observations have been made, definitive results must await an extensive study.
Resume
Another discussant asked what is the difference between the effect of barbiturates and anticholinergic drugs on the EEG.
One discussant felt that the EEG was a poor tool, since it could be modified in only two ways, synchronization or desynchronization, and firm conclusions should not be drawn from such changes. He therefore felt that analogies between diethazine and Tofranil were dubious and that nausea was not a specific effect of Tofranil. He wondered if EEG changes would always exist in the absence of nausea, and felt it important to correlate EEG changes with clinical changes.
In replying to these comments, Dr. Fink stated that he considered Tofrjinil an anticholinergic drug because of its similarity to other anticholinergic drugs in regard to its EEG patterns. Dr. Fink recalled that Dr. Sigg's paper had also indicated that Tofranil was an anticholinergic drug. Many anticholinergic compounds appear to have rather specific central effects, and some are also experimental hallucinogens. In his experience, barbiturates produce not desynchronization, but rather synchronization. This becomes clear if the factors of dosage and time are considered. Thus the initial effect is hypersynchronization; if the drug is continued, sleep is of course produced and the initial effect disappears.
The author replied to the criticism of his use of EEG. He agreed that it is a poor tool in many respects, but that it is possible to analyze EEG records for synchronization, desynchronization and frequency shifts. One obtains different patterns with different agents even in the same patient. Dr. Fink explained that he was making a long-term study, and hoped that more conclusive data could be offered atala ter rime.
